Cross functional "excellence teams", a multichannel approach to reduce "information asymmetry" for customers, calibrating prices to improve access and penetrating deeper into middle and rural India are some of the core components of GlaxoSmithKline PLC’s ongoing effort to fundamentally overhaul its business in India.
INTERVIEW: A Revolution At GSK India
Brace for GSK India's new avatar. The British multinational is revamping its business model in India and donning a new approach to create, deliver and capture value via a "one team" effort as it strives to emerge as the fastest growing pharma multinational in the country by 2020.
More from Focus On Asia
More from Scrip
• By
Analysts expect a limited impact on South Korean pharma from US tariffs, even if imposed at a later date. Meanwhile, the early June domestic presidential election is set to determine the direction of policies in the sector.
• By
The company plans a tiered sales approach as it targets endocrinologists for hypothalamic obesity, which is more widely diagnosed than its current indication for Bardet-Biedl syndrome.
• By
There were six biopharma initial public offerings on Western stock exchanges, including five in the US, during the first quarter, but plunging stock values could halt further IPOs.